Torrent Pharmaceuticals reported a roughly 57% increase in third-quarter profit, driven by robust demand in the home market, Germany, and Brazil. The drugmaker's overall net profit for the quarter ended December 31 was ₹443 crore, up from ₹283...
Worldwide pharma significant Lupin Restricted (Lupin) reported that it has gotten endorsement from the US Food and Medication Organization (FDA) for its Truncated New Medication Application for dronedarone tablets USP, 400 mg, to showcase a...
Benuvia Operations, LLC, a U.S.-based drug developer and manufacturer of active pharmaceutical ingredients (APIs) with specialized expertise in controlled substances (cannabinoids and psychedelics), and Societal CDMO, Inc., a contract development...
Lupin Digital Health, the leading evidence-based digital diagnostics (DTx) platform, and the American College of Cardiology (ACC), the world scientific leader in cardiology, have introduced the world's first Digital Recovery Certification.
Astellas Pharma Inc., a pharmaceutical company operating in more than 70 countries worldwide, announced a strategic partnership with Mass General Brigham, focused on translational medicine and early-stage development, to create an integrated approach
In the pre-election budget, which did not mention any changes in direct or indirect taxes, Union Finance Minister Nirmala Seetharaman announced new plans to promote bio-based manufacturing in biomedicine and plans to set up more medical colleges.
Astellas Pharma Canada, Inc., the Canadian subsidiary of Astellas Pharma Inc. of Tokyo, announced that Health Canada has approved a new drug application for Xtandi (enzalutamide) in the advanced treatment area of prostate cancer.
.jpg "Stryker introduces Tornier Shoulder Arthroplasty Portfolio in India")
Stryker, one of the world’s leading medical technologies companies, has introduced the Tornier shoulder arthroplasty portfolio in India and launched its first new Tornier product, the PerformTM Humeral Stem today at Shoulder Conclave in Pune...
Cancer vaccines will become more expensive after the government considers adding the human papillomavirus (HPV) vaccine to the national immunization program
Piramal Pharma Ltd detailed a 14% year-on-year ascend in its united income from tasks to ₹1,959 crore in the December finished quarter (Q3FY24), driven areas of strength for by across its verticals.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")